These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29552922)

  • 41. Treatment of hepatitis B and C in children.
    El-Shabrawi M; Hassanin F
    Minerva Pediatr; 2014 Oct; 66(5):473-89. PubMed ID: 25253190
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
    Michielsen P; Ho E; Francque S
    Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis C treatment as prevention: evidence, feasibility, and challenges.
    Hajarizadeh B; Grebely J; Martinello M; Matthews GV; Lloyd AR; Dore GJ
    Lancet Gastroenterol Hepatol; 2016 Dec; 1(4):317-327. PubMed ID: 28404202
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets.
    Ploss A; Dubuisson J
    Gut; 2012 May; 61 Suppl 1():i25-35. PubMed ID: 22504917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pioneering a Global Cure for Chronic Hepatitis C Virus Infection.
    Vilarinho S; Lifton RP
    Cell; 2016 Sep; 167(1):12-15. PubMed ID: 27634325
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevention of hepatocellular carcinoma complicating chronic hepatitis C.
    Ueno Y; Sollano JD; Farrell GC
    J Gastroenterol Hepatol; 2009 Apr; 24(4):531-6. PubMed ID: 19368633
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estimates on HCV disease burden worldwide - filling the gaps.
    Wedemeyer H; Dore GJ; Ward JW
    J Viral Hepat; 2015 Jan; 22 Suppl 1():1-5. PubMed ID: 25560838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatitis C Virus and Antiviral Drug Resistance.
    Kim S; Han KH; Ahn SH
    Gut Liver; 2016 Nov; 10(6):890-895. PubMed ID: 27784846
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses.
    Agrawal B; Kumar R
    World J Gastroenterol; 2016 Jul; 22(25):5623-6. PubMed ID: 27433078
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era.
    Teriaky A; Reau N
    Clin Liver Dis; 2015 Nov; 19(4):591-604, v. PubMed ID: 26466649
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.
    Wilson EM; Rosenthal ES; Kattakuzhy S; Tang L; Kottilil S
    Clin Microbiol Rev; 2017 Jan; 30(1):23-42. PubMed ID: 27795306
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adverse effects of drugs in the treatment of viral hepatitis.
    Negro F
    Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):183-92. PubMed ID: 20227031
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements.
    Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma
    J Gastroenterol Hepatol; 2010 Apr; 25(4):657-63. PubMed ID: 20492323
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Exploring the health education model for chronic hepatitis C micro-elimination in Guizhou Province from a global perspectives].
    Luo XH; Liang YD; Peng H; Ning JH
    Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):816-819. PubMed ID: 33105923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of hepatitis C: momentum still needed.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2018 May; 3(5):289. PubMed ID: 29644967
    [No Abstract]   [Full Text] [Related]  

  • 57. Striving for hepatitis C virus elimination or control?
    Dore GJ
    Lancet Gastroenterol Hepatol; 2018 May; 3(5):295-297. PubMed ID: 29644970
    [No Abstract]   [Full Text] [Related]  

  • 58. [Opportunities and challenges for the treatment of chronic hepatitis C].
    Luo BF; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):161-163. PubMed ID: 28482400
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeted direct-acting antiviral treatment for chronic hepatitis C: A financial reality or an obstacle to elimination?
    Hellard M; Pedrana A; Scott N
    J Hepatol; 2017 Feb; 66(2):270-272. PubMed ID: 27884764
    [No Abstract]   [Full Text] [Related]  

  • 60. [Elimination of hepatitis C virus infection].
    Pol S
    Presse Med; 2019 Jan; 48(1 Pt 1):1-3. PubMed ID: 30784420
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.